These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31171895)

  • 1. Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma.
    Barone M; Viggiani MT; Losurdo G; Principi M; Leo AD
    World J Gastroenterol; 2019 May; 25(20):2524-2538. PubMed ID: 31171895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
    Yoshiji H; Kuriyama S; Fukui H
    Tumour Biol; 2002; 23(6):348-56. PubMed ID: 12677092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.
    Yoshiji H; Noguchi R; Toyohara M; Ikenaka Y; Kitade M; Kaji K; Yamazaki M; Yamao J; Mitoro A; Sawai M; Yoshida M; Fujimoto M; Tsujimoto T; Kawaratani H; Uemura M; Fukui H
    J Hepatol; 2009 Aug; 51(2):315-21. PubMed ID: 19501932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases.
    Yoshiji H; Noguchi R; Ikenaka Y; Kitade M; Kaji K; Tsujimoto T; Uemura M; Fukui H
    Curr Med Chem; 2007; 14(26):2749-54. PubMed ID: 18045121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
    Ho CM; Lee CH; Lee MC; Zhang JF; Wang JY; Hu RH; Lee PH
    BMC Cancer; 2018 Apr; 18(1):401. PubMed ID: 29631561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of renin-angiotensin system in hepatocellular carcinoma.
    Yoshiji H; Noguchi R; Ikenaka Y; Kaji K; Aihara Y; Fukui H
    Curr Cancer Drug Targets; 2011 May; 11(4):431-41. PubMed ID: 21395547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.
    Wu HY; Huang JW; Lin HJ; Liao WC; Peng YS; Hung KY; Wu KD; Tu YK; Chien KL
    BMJ; 2013 Oct; 347():f6008. PubMed ID: 24157497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.
    Xie X; Liu Y; Perkovic V; Li X; Ninomiya T; Hou W; Zhao N; Liu L; Lv J; Zhang H; Wang H
    Am J Kidney Dis; 2016 May; 67(5):728-41. PubMed ID: 26597926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches to blockade of the renin-angiotensin-aldosterone system: evidence from randomized controlled trials (RCTs) of angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers--questions remain unsolved.
    Ueda S
    J Pharmacol Sci; 2010; 113(4):292-5. PubMed ID: 20675956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer.
    Khoshghamat N; Jafari N; Toloue-Pouya V; Azami S; Mirnourbakhsh SH; Khazaei M; Ferns GA; Rajabian M; Avan A
    Life Sci; 2021 Apr; 270():119118. PubMed ID: 33548284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial.
    Yoshiji H; Noguchi R; Ikenaka Y; Kaji K; Aihara Y; Yamazaki M; Yamao J; Toyohara M; Mitoro A; Sawai M; Yoshida M; Morioka C; Fujimoto M; Uemura M; Fukui H
    Oncol Rep; 2011 Dec; 26(6):1547-53. PubMed ID: 21874260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients.
    Facciorusso A; Del Prete V; Crucinio N; Muscatiello N; Carr BI; Di Leo A; Barone M
    J Gastroenterol Hepatol; 2015 Nov; 30(11):1643-50. PubMed ID: 25974743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.
    Wang K; Hu J; Luo T; Wang Y; Yang S; Qing H; Cheng Q; Li Q
    Kidney Blood Press Res; 2018; 43(3):768-779. PubMed ID: 29794446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis.
    Wang B; Wang F; Zhang Y; Zhao SH; Zhao WJ; Yan SL; Wang YG
    Lancet Diabetes Endocrinol; 2015 Apr; 3(4):263-74. PubMed ID: 25660574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.
    Li EC; Heran BS; Wright JM
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009096. PubMed ID: 25148386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.
    Kunz R; Friedrich C; Wolbers M; Mann JF
    Ann Intern Med; 2008 Jan; 148(1):30-48. PubMed ID: 17984482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The renin-angiotensin system: the role of inhibitors, blockers, and genetic polymorphisms in the treatment and prevention of heart failure.
    Hebert PR; Foody JM; Hennekens CH
    Curr Vasc Pharmacol; 2003 Mar; 1(1):33-9. PubMed ID: 15320851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials.
    Benjamin DJ; Haslam A; Prasad V
    Cancer Med; 2024 Mar; 13(5):e7049. PubMed ID: 38491813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.